| Business Summary |
| A clinical stage biotechnology company, which is engaged in the discovery, development and commercialization of novel biotherapeutics for unmet medical needs, with an emphasis on inflammatory and oncology indications. |
| General Information |
300 Technology Square
Cambridge, MA 02139
|
| www.dyax.com |
| Industry : Drugs |
| Sector: Health Care |
| Employees: 164 |
| CEO: Gustav A. Christensen |
| Short Interest |
| Current Month (Mil) |
2.89 |
| Previous Month (Mil) |
2.40 |
| Short Interest Ratio (Days) |
7.80 |
| Management Effectiveness |
| Return on Equity |
n.a. |
| Return on Assets |
-87.40 |
| Return on Investments |
-464.00 |
| Profitability |
| Gross Margin |
n.a. |
| EBIT Margin |
-76.10 |
| Profit Margin |
-96.40 |
Connect with TheStreet